Wuxi People's Hospital

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults

  NCT07835152· Phase 3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults

  NCT07792681· Phase 2/3· Brise Pharmaceuticals Co., Ltd.· Source

• Recruiting

  Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers

  NCT07600125· Xijing Hospital· Source

• Not yet recruiting

  R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma

  NCT07764601· WEI XU· Source

• Recruiting

  Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities

  NCT07781124· Vantive Health LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis

  NCT07453004· Phase 2· TJ Biopharma Co., Ltd.· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

  NCT07486479· Phase 3· The First Affiliated Hospital of Soochow University· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT07369011· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Takeda· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

  NCT06952530· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

  NCT06948422· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

  NCT06862869· Hoffmann-La Roche· Source

• Active, not recruiting

  A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

  NCT06948435· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy

  NCT06817265· Phase 3· Beletalent (Zhuhai) Pharmaceutical Co., Ltd· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

  NCT06774664· Phase 1/2· Sinocelltech Ltd.· Source

• Active, not recruiting

  Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

  NCT06578247· Phase 3· Daiichi Sankyo· Source

• Not yet recruiting

  The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).

  NCT06606509· Nanjing First Hospital, Nanjing Medical University· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06589986· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Recruiting

  JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

  NCT06416410· Phase 3· Allist Pharmaceuticals, Inc.· Source

• Active, not recruiting

  SIM0718 Treatment of Asthma Clinical Study

  NCT06488755· Phase 3· Simcere Pharmaceutical Co., Ltd· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Henagliflozin's Impact on Prediabetes Remission

  NCT06448130· Phase 4· Shandong Provincial Hospital· Source

• Recruiting

  Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival

  NCT06256354· Peking University First Hospital· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

  NCT06387069· Phase 3· Hutchmed· Source

• Recruiting

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

  NCT06247046· Phase 3· Guangzhou Zhiyi Biotechnology Co., Ltd.· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

  NCT06052059· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma

  NCT05954910· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Telitacicept for IgA Nephropathy (TELIGAN)

  NCT05799287· Phase 3· RemeGen Co., Ltd.· Source

• Recruiting

  Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

  NCT05410925· Phase 4· The First Affiliated Hospital with Nanjing Medical University· Source

• Active, not recruiting

  A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05572515· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05528510· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

Showing 50 of 61.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease3 recruiting
• Lung cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Bronchiectasis2 recruiting
• Chronic kidney disease2 recruiting
• Coronary artery disease2 recruiting
• IgA nephropathy2 recruiting
• Migraine2 recruiting
• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• Colorectal cancer1 recruiting
• Diabetic eye disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gout1 recruiting
• Irritable bowel syndrome1 recruiting
• Obstructive sleep apnoea1 recruiting
• Peripheral artery disease1 recruiting
• Prostate cancer1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

  NCT06848400· Nanfang Hospital, Southern Medical University· Source

• Completed

  A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

  NCT06738979· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT06649045· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Akeso· Source

• Completed

  Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients

  NCT06492031· Vantive Health LLC· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Optimization of DE-CTPA Images and Diagnostic Pathway: Using Low Concentration Iodine Contrast Material

  NCT06212882· Wuxi People's Hospital· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  NCT05872620· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

  NCT05810038· Phase 3· Pfizer· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)

  NCT05810948· Phase 2· argenx· Source

• Completed

  A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

  NCT05691712· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

  NCT05590793· Phase 3· Ipsen· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

  NCT05412004· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

  NCT05362058· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

  NCT05029921· Phase 4· Janssen Research & Development, LLC· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Novo Nordisk A/S· Source

• Completed

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Daiichi Sankyo· Source

• Completed

  A Study of Ninlaro in Real World Clinical Practice in China

  NCT04328662· Takeda· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Gastric and oesophageal cancer34 works · 2 trials
• Idiopathic pulmonary fibrosis12 works · 3 trials